| Literature DB >> 30544551 |
Ricardo Trindade1, Tomas Albrektsson2,3, Silvia Galli4, Zdenka Prgomet5, Pentti Tengvall6, Ann Wennerberg7.
Abstract
Bone anchored biomaterials have become an indispensable solution for the restoration of lost dental elements and for skeletal joint replacements. However, a thorough understanding is still lacking in terms of the biological mechanisms leading to osseointegration and its contrast, unwanted peri-implant bone loss. We have previously hypothesized on the participation of immune mechanisms in such processes, and later demonstrated enhanced bone immune activation up to 4 weeks around titanium implants. The current experimental study explored and compared in a rabbit tibia model after 10 days of healing time, the bone inflammation/immunological reaction at mRNA level towards titanium, polyether ether ketone (PEEK) and copper compared to a Sham control. Samples from the test and control sites were, after a healing period, processed for gene expression analysis (polymerase chain reaction, (qPCR)) and decalcified histology tissue analysis. All materials displayed immune activation and suppression of bone resorption, when compared to sham. The M1 (inflammatory)/M2 (reparative) -macrophage phenotype balance was correlated to the proximity and volume of bone growth at the implant vicinity, with titanium demonstrating a M2-phenotype at 10 days, whereas copper and PEEK were still dealing with a mixed M1- and M2-phenotype environment. Titanium was the only material showing adequate bone growth and proximity inside the implant threads. There was a consistent upregulation of (T-cell surface glycoprotein CD4) CD4 and downregulation of (T-cell transmembrane glycoprotein CD8) CD8, indicating a CD4-lymphocyte phenotype driven reaction around all materials at 10 days.Entities:
Keywords: biomaterials; foreign body reaction; immune system; in vivo study; osseointegration
Year: 2018 PMID: 30544551 PMCID: PMC6307090 DOI: 10.3390/jcm7120526
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Gene sequences.
| Primer | Forward Sequence | Reverse Sequence | Accession nr/Transcript ID |
|---|---|---|---|
|
| TTCATCCGCCACATTGCCC | GTCCTGCCACTTCACCAAGA | NM_001082102.1 |
|
| TTTCCCCAGCTCTCCACCTC | CGATGATGAGGGGCACCAAG | ENSOCUT00000010382 |
|
| TTCAACCTGGAGACTGAGAACAC | TCAAACTGGACCACGCTCTG | ENSOCUT00000001589 |
|
| TCTGAAAATCCTGGGCTGGG | TTCATTCCCGCGTTCCGTAG | ENSOCUT00000004218 |
|
| GGATCATTGGAGCCCCTTTCTC | TCAAGCAGACCAGCCTTTCTC | NM_001082108.1 |
|
| CTACCTCCACCACAAGGTGTC | CCAGTGTAGTCTGTCTGGCTT | ENSOCUT00000024099 |
|
| GCAGCCTCGTATCCCCAG | GGTTGACGCTCCACACCA | ENSOCUT00000000154 |
|
| GGAACTCTCGCTCAGGCTC | ACATTCTTGATCTTCTCCAGCAAC | ENSOCUT00000030714 |
|
| TGTGTGAATGCGAGGAAGGG | AACTGTATTCCGCTCTGGGG | ENSOCUT00000011149 |
|
| GAAGGTTCATGGTTCGATCTGG | CCAAGAGGACAGGCTCACTTT | ENSOCUT00000024354 |
|
| TTACTTCAGTGGCGTGCAGA | CGATCTGGGCTGAGACGTTG | NM_001081988.1 |
|
| GGAACCGGGGCATTGACTCT | TGTACCCTCTGCATTTGGCTG | NM_001082641.1 |
|
| CAAGGCGAGGGCGATCTT | ATGCGGATGGCGACTTCTTT | NM_001082148.1 |
|
| ACTCTGTCGAGAAGGAACGGG | CCTTGATTTGTTGATGCTGGCTG | NM_001082286.1 |
|
| CATGTCAGTCAACCCCTGCT | GCGAATGGTTTTGCTCCCTG | ENSOCUT00000007435 |
|
| TCCTGCTGTTCACTTTCTCGG | CATGTTCCCATCCTTGTTTACACTT | ENSOCUT00000033915 |
|
| TGGTGTTGGGTGGAGTGACC | AGAGTGAAGCCTCTGTTGCATT | ENSOCUT00000031985 |
|
| ACCACTGTCTCCTCCCAAGT | GCAATCTTCATACCGCCAACA | NM_001082712.1 |
|
| TCCAAAACTCTGCAACCTTAACA | AAATGCTTTGACACAACTTCCA | ENSOCUT00000005683 |
|
| ACGTCAACTGCTGCATCAACC | AGGCTGGGGAGAGACTTGC | ENSOCUT00000029180 |
|
| CCTGGGGACAGGAAGATGATGAC | CAGCACCACACGGGTTCCA | NM_001082001.1 |
|
| CAACTGGAAACATGCGAACCA | TTGATGACCAGGGGGAAAGA | NM_001082313.2 |
|
| GGCGTCTACTTCTGCATGACC | GAACCGGCACACTCTCTTCT | ENSOCUT00000009383 |
|
| GGATGTATGTCTGTCGCCGT | AAGCAAAGCCACAACTGGAA | ENSOCUT00000028895 |
|
| GGTGAAGGTCGGAGTGAACGG | CATGTAGACCATGTAGTGGAGGTCA | NM_001082253.1 |
|
| TCATTCCAAATATCGTGAGATGCC | TACACAAATGCGATGCTGCC | NM_001101683.1 |
|
| TGCAGACAAGGAACAGTGGA | CCCAGGTAGTGTAGCCCTT | NM_001082277.1 |
NCF-1, neutrophil cytosolic factor 1; CD68, macrosialin; CD11b, macrophage marker; CD14, monocyte differentiation antigen CD14; ARG1, Arginase 1; IL-4, Interleukin 4; IL-13, Interleukin 13; M-CSF, colony stimulating factor-macrophage; OPG, osteoprotegerin; RANKL, Receptor activator of nuclear factor kappa-B ligand; TRAP, tartrate resistant acid phosphatase; CathK, cathepsin K; PPAR-γ, peroxisome proliferator activated receptor gamma; C3, complement component 3; C3aR1, complement component 3a receptor 1; CD46, complement regulatory protein; CD55, decay accelerating factor for complement; CD59, complement regulatory protein; C5, complement component 5; C5aR1, complement component 5a receptor 1; CD3, T-cell surface glycoprotein CD3; CD4, T-cell surface glycoprotein CD4; CD8, T-cell transmembrane glycoprotein CD8; CD19, B-lymphocyte surface protein CD19; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ACT-β, actin beta; LDHA, lactate dehydrogenase A.
Correspondence between studied gene expression and biological entities.
| Biological Entity | Gene |
|---|---|
| Neutrophil | NCF-1 |
| Macrophage | CD68, CD11b, CD14, ARG1 |
| Macrophage fusion | IL-4, IL-13, M-CSF |
| Bone resorption | OPG, RANKL, TRAP, CathK, PPAR-γ |
| Complement | Activation: C3, C3aR1, C5, C5aR1 Inhibition: CD46, CD55, CD59 |
| T-lymphocytes | CD3, CD4, CD8 |
| B-lymphocytes | CD19 |
| Reference genes | GAPDH, ACT-β, LDHA |
Gene expression Ti vs. Sham.
|
|
|
|
| ARG1 | 1.82 | 0.0254 |
| CD4 | 2.03 | 0.0598 |
|
|
|
|
| M-CSF | −2.23 | 0.0004 |
| PPAR-G | −3.07 | 0.0008 |
| RANKL | −2.24 | 0.0678 |
| OPG | −1.85 | 0.5711 |
| C3aR1 | −3.55 | 0.0137 |
| CD8b | −2.80 | 0.0195 |
Figure 1Volcano plot comparing the gene expression of Ti versus Sh at 10 days. Downregulation (vertical green line) and Upregulation (vertical red line) set a ×2 regulation. Statistical significance (horizontal blue line) set at p < 0.05—Marker is significant when above blue line.
Gene expression PEEK vs. Sham.
|
|
|
|
| ARG1 | 3.11 | 0.1091 |
| CD68 | 2.00 | 0.4304 |
| NCF1 | 2.61 | 0.1556 |
| CD4 | 1.95 | 0.0771 |
|
|
|
|
| PPAR-G | −4.81 | 0.0009 |
| RANKL | −3.16 | 0.0286 |
| OPG | −3.13 | 0.0210 |
| TRAP | −1.91 | 0.0109 |
| CATHK | −1.75 | 0.0985 |
| C5 | −2.73 | 0.0044 |
| CD59 | −1.87 | 0.0181 |
| CD55 | −1.81 | 0.0578 |
| C3aR1 | −2.84 | 0.0601 |
| CD8b | −2.86 | 0.0044 |
Figure 2Volcano plot comparing the gene expression of PEEK versus Sh at 10 days. Downregulation (vertical green line) and Upregulation (vertical red line) set a ×2 regulation. Statistical significance (horizontal blue line) set at p < 0.05—Marker is significant when above blue line.
Gene expression Cu vs. Sham.
|
|
|
|
| ARG1 | 25.74 | 0.0072 |
| NCF1 | 3.41 | 0.0234 |
| CD4 | 3.11 | 0.0178 |
| CD19 | 1.88 | 0.3768 |
| C5aR1 | 2.03 | 0.1021 |
| CD68 | 1.80 | 0.4153 |
| CD11b | 1.79 | 0.5131 |
| CD14 | 1.61 | 0.6120 |
|
|
|
|
| PPAR-G | −5.28 | 0.0001 |
| RANKL | −1.71 | 0.1301 |
| OPG | −3.74 | 0.2815 |
| TRAP | −2.25 | 0.0676 |
| C5 | −1.66 | 0.0007 |
| CD59 | −2.01 | 0.3376 |
| C3aR1 | −2.14 | 0.2071 |
| CD8b | −2.09 | 0.0906 |
Figure 3Volcano plot comparing the gene expression of Cu versus Sh at 10 days. Downregulation (vertical green line) and Upregulation (vertical red line) set a ×2 regulation. Statistical significance (horizontal blue line) set at p < 0.05—Marker is significant when above blue line.
Figure 4The 10 days Sh site. Bone remodeling with new bone formation around the osteotomy site. Defect is isolated from the marrow space. Scale bars, clockwise: 5 mm, 1 mm, 250 µm and 100 µm.
Figure 5The 10 days Ti site. Bone remodeling and new bone formation around the implant site, isolating it from the marrow space. Scale bars, clockwise: 5 mm, 500 µm and 50 µm.
Figure 6The 10 days Cu site. No bone on the immediate implant vicinity. FBGC, foreign body giant cells; Oc, osteoclast actively remodeling old bone; Ob, Seam of osteoblasts producing new bone (part of the remodeling); IO, Implant/Osteotomy. Reaction to Cu divided in 3 zones, representing the 3 phenomena around implant materials in the bone: From the implant surface Lytic/Inflammatory area, Fibroproliferative area and Osteoproliferative area. The latter two represent an attempt to isolate the material from the marrow cavity. No osseointegration is viable at this time point. Theoretically, around Ti the same phenomena exist, but at a different balance, allowing for osseointegration, through direct bon-to-implant contact. Inflammatory area is highly vascularized. Scale bars 5 mm (left) and 100 µm (right).
Figure 7The 10 days PEEK. NB, new bone; forming only in the areas adjacent to cortical bone, while most other interfacial tissue shows no bone formation. P, proliferative area; no visible calcified tissue formation, but for some isolated calcified bone areas (CB, calcified bone). Scale bars, clockwise: 5 mm, 1 mm and 250 µm.
Surface roughness analysis.
| Surface Roughness | Sa µm Mean | Ssk Mean | Sds 1/µm2 Mean | Sdr % Mean |
|---|---|---|---|---|
| Copper | 0.40 | 1.2 | 0.28 | 47 |
| Titanium | 0.75 | −0.02 | 0.25 | 66 |
| PEEK | 0.56 | −0.23 | 0.31 | 69 |
Sa, describes the average height distribution measured in µm; Sds, a measure of the density of summits over the measured area, measured in 1/µm2; Ssk (skewness), a parameter that describes the asymmetry of the surface deviation from the mean plane; Sdr, describes the surface enlargement compared to a totally flat reference area, measured in %.